• 1. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 2. Aluminium complexes with thio-phosphorus ligands: syntheses and characterisations of [Al2(CyPS3)2(CyPHS2)2] and [Al(S2PPh2)3]?
  Robert P. Davies,Maria A. Giménez,Laura Patel,Andrew J. P. White Dalton Trans., 2008, 5705-5707
• 3. An integrated microfluidic 3D tumor system for parallel and high-throughput chemotherapy evaluation?
  Dan Liu,Rui Hu,Zhongchao Huang,Meilin Sun,Kai Han Analyst, 2020,145, 6447-6455
• 4. Alt-proteins: A promising future
• 5. An aptasensor for detection of potassium ions based on RecJf exonuclease mediated signal amplification
  Bidou Wang,Xifeng Chen Analyst, 2014,139, 5695-5699

Introduction to 1-Cyclopropyl-1H-imidazole-4-carboxylic acid (CAS No. 1368466-66-3)

1-Cyclopropyl-1H-imidazole-4-carboxylic acid, identified by its Chemical Abstracts Service (CAS) number 1368466-66-3, is a heterocyclic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal biology. This compound belongs to the imidazole class, a structural motif widely recognized for its biological activity and versatility in drug design. The presence of a cyclopropyl substituent at the 1-position of the imidazole ring introduces unique electronic and steric properties, making it a valuable scaffold for developing novel therapeutic agents.

The 1-cyclopropyl-1H-imidazole-4-carboxylic acid structure is characterized by a five-membered aromatic ring containing two nitrogen atoms, with a carboxylic acid functional group at the 4-position and a cyclopropyl group attached to the 1-position. This configuration imparts distinct physicochemical properties, including solubility, stability, and metabolic profiles, which are critical factors in drug development. The cyclopropyl group, in particular, is known to enhance binding affinity and selectivity by introducing steric hindrance and modulating electronic distributions.

In recent years, there has been a surge in research focused on imidazole derivatives due to their broad spectrum of biological activities. 1-Cyclopropyl-1H-imidazole-4-carboxylic acid has been investigated for its potential in various pharmacological applications, including antimicrobial, anti-inflammatory, and anticancer therapies. The carboxylic acid moiety at the 4-position provides a reactive site for further functionalization, enabling the synthesis of more complex derivatives with tailored biological properties.

One of the most compelling aspects of 1-cyclopropyl-1H-imidazole-4-carboxylic acid is its role as a key intermediate in the synthesis of biologically active molecules. Researchers have leveraged this scaffold to develop inhibitors targeting enzymes involved in critical metabolic pathways. For instance, studies have demonstrated its utility in generating compounds that modulate the activity of poly(ADP-ribose) polymerases (PARPs), which are implicated in DNA repair and inflammation. The cyclopropyl group has been shown to enhance binding interactions with target proteins, leading to improved efficacy and selectivity.

The pharmaceutical industry has shown particular interest in 1-cyclopropyl-1H-imidazole-4-carboxylic acid due to its potential as a lead compound for drug discovery. Its structural features make it an ideal candidate for further derivatization, allowing chemists to explore diverse chemical spaces while maintaining core pharmacophoric elements. This flexibility has enabled the development of novel analogs with enhanced pharmacokinetic profiles and reduced side effects.

Recent advancements in computational chemistry have further accelerated the exploration of 1-cyclopropyl-1H-imidazole-4-carboxylic acid derivatives. Molecular docking studies have identified promising scaffolds for drug development by predicting binding affinities and interactions with biological targets. These computational approaches have complemented experimental efforts, providing insights into structure-activity relationships that guide rational drug design.

In clinical settings, 1-cyclopropyl-1H-imidazole-4-carboxylic acid derivatives have been evaluated in preclinical models for their therapeutic potential. Preliminary results suggest that certain analogs exhibit significant efficacy against cancer cell lines by inhibiting key signaling pathways involved in tumor growth and progression. Additionally, their ability to modulate inflammatory responses has opened avenues for treating chronic inflammatory diseases.

The synthesis of 1-cyclopropyl-1H-imidazole-4-carboxylic acid involves multi-step organic transformations that highlight its synthetic accessibility. Modern synthetic methodologies have improved yields and purity levels, making it feasible to produce sufficient quantities for both research and commercial purposes. Advances in green chemistry principles have also been applied to optimize synthetic routes, reducing environmental impact while maintaining efficiency.

The future prospects of 1-cyclopropyl-1H-imidazole-4-carboxylic acid are promising, with ongoing research aimed at expanding its therapeutic applications. Collaborative efforts between academia and industry are expected to yield innovative drug candidates based on this scaffold. As computational tools continue to evolve, the discovery of new derivatives will likely accelerate, further solidifying its importance in medicinal chemistry.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)